EDAP TMS SA reported the publication of its HIFI study on December 4, 2024, demonstrating that its Focal One robotic HIFU is as effective as surgery for treating localized prostate cancer, with better outcomes for urinary continence and erectile function. The study involved 3,328 patients over seven years and found 90% survival without salvage treatment after HIFU compared to 86% for surgery.